Catalyst Pharmaceuticals (CPRX) Total Liabilities (2010 - 2026)

Catalyst Pharmaceuticals (CPRX) has 17 years of Total Liabilities data on file, last reported at $134.9 million in Q1 2026.

• Quarterly Total Liabilities rose 17.74% year-over-year to $134.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $134.9 million (up 17.74% YoY) and the FY2025 annual result came in at $149.7 million, up 20.95% from the prior year.
• Total Liabilities declined to $134.9 million in Q1 2026, from $149.7 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $149.7 million in Q4 2025 to a low of $26.2 million in Q2 2022.
• A 5-year average of $90.9 million and a median of $85.3 million in 2024 frame the typical range for Total Liabilities.
• The widest YoY moves for Total Liabilities: up 175.0% in 2023, down 2.52% in 2023.
• Tracing CPRX's Total Liabilities over 5 years: stood at $75.2 million in 2022, then rose by 9.34% to $82.2 million in 2023, then jumped by 50.52% to $123.8 million in 2024, then increased by 20.95% to $149.7 million in 2025, then slipped by 9.88% to $134.9 million in 2026.
• The last three Total Liabilities figures came in at $134.9 million (Q1 2026), $149.7 million (Q4 2025), and $131.4 million (Q3 2025), per Business Quant data.